Zelira Therapeutics Boosts Capital with Chairman’s Loan
Company Announcements

Zelira Therapeutics Boosts Capital with Chairman’s Loan

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics has secured a $1.4 million unsecured loan from its Chairman Osagie Imasogie, intended to advance the HOPE SPV clinical trial and for general working capital. The loan could convert to shares at $0.40, a significant premium over the recent closing price, pending shareholder approval at the upcoming AGM. This strategic financial move is aimed at bolstering the company’s efforts in clinically validated cannabis medicines and other proprietary revenue-generating products.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics’ Financials: Borrowings Boost Cash Flow
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Advances in FDA Trials and Product Development
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Schedules Hybrid 2024 AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App